Kossaczka Z, Bystricky S, Bryla D A, Shiloach J, Robbins J B, Szu S C
Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
Infect Immun. 1997 Jun;65(6):2088-93. doi: 10.1128/iai.65.6.2088-2093.1997.
The Vi capsular polysaccharide of Salmonella typhi, a licensed vaccine for typhoid fever in individuals > or = 5 years old, induces low and short-lived antibodies in children, and reinjection does not elicit booster responses at any age. Its immunogenicity was improved by binding Vi to proteins by using N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) as a linker. Similar findings were observed with the structurally related, di-O-acetyl derivative of pectin [poly-alpha(1-->4)-D-GalpA] designated OAcP. Protein conjugates of Vi and OAcP were synthesized by carbodiimide-mediated synthesis with adipic acid dihydrazide (ADH) as the linker. Hydrazide groups were introduced into proteins (bovine serum albumin or recombinant Pseudomonas aeruginosa exoprotein A) by treatment with ADH and 1-ethyl-3(3-dimethylaminopropyl carbodiimide (EDC). The resultant adipic acid hydrazide derivatives (AH-proteins), containing 2.3 to 3.4% AH, had antigenic and physicochemical properties similar to those of the native proteins. The AH-proteins were bound to Vi and OAcP by treatment with EDC. The immunogenicity of Vi or OAcP, alone or as protein conjugates, was evaluated in young outbred mice and guinea pigs by subcutaneous injection of 2.5 and 5.0 microg, respectively, of polysaccharide, and antibodies were measured by enzyme-linked immunosorbent assay. All conjugates were significantly more immunogenic than Vi or OAcP alone and induced booster responses with 5- to 25-fold increases of antibodies. Vi conjugates were significantly more immunogenic than their OAcP analogs. A carboxymethyl derivative of yeast beta-glucan enhanced the anti-Vi response elicited by an OAcP conjugate but had no effect on the immunogenicity of Vi or of OAcP alone. Vi and OAcP conjugates synthesized by this scheme will be evaluated clinically.
伤寒沙门氏菌Vi荚膜多糖是一种已获许可用于5岁及以上个体伤寒热的疫苗,它在儿童中诱导产生的抗体水平低且持续时间短,并且再次注射在任何年龄都不会引发加强反应。通过使用N-琥珀酰亚胺基-3-(2-吡啶二硫基)丙酸酯(SPDP)作为连接剂将Vi与蛋白质结合,其免疫原性得到了改善。对于结构相关的果胶二-O-乙酰衍生物[聚-α(1→4)-D-半乳糖醛酸](称为OAcP)也观察到了类似的结果。Vi和OAcP的蛋白质偶联物通过以己二酸二酰肼(ADH)作为连接剂的碳二亚胺介导合成法合成。通过用ADH和1-乙基-3-(3-二甲基氨基丙基)碳二亚胺(EDC)处理,将酰肼基团引入蛋白质(牛血清白蛋白或重组铜绿假单胞菌外蛋白A)中。所得的己二酸酰肼衍生物(AH-蛋白质)含有2.3%至3.4%的AH,具有与天然蛋白质相似的抗原性和物理化学性质。通过用EDC处理,将AH-蛋白质与Vi和OAcP结合。分别通过皮下注射2.5和5.0微克多糖,在幼年远交系小鼠和豚鼠中评估Vi或OAcP单独或作为蛋白质偶联物的免疫原性,并通过酶联免疫吸附测定法测量抗体。所有偶联物的免疫原性均明显高于单独的Vi或OAcP,并诱导产生抗体增加5至25倍的加强反应。Vi偶联物的免疫原性明显高于其OAcP类似物。酵母β-葡聚糖的羧甲基衍生物增强了OAcP偶联物引发的抗Vi反应,但对Vi或单独的OAcP的免疫原性没有影响。通过该方案合成的Vi和OAcP偶联物将进行临床评估。